Precipio, Inc. filed its 10-Q report, highlighting Q3-2025 financial results. Revenues reached $6.8M, a 30% increase YoY. Adjusted EBITDA was $469K, up $369K YoY. Cash flow swung from ($148K) to $285K generated in Q3-2025. CEO Ilan Danieli praised the positive EBITDA and cash generation, creating growth opportunities.

Pathology Services Division saw a 20% revenue increase to $6.0M in Q3-2025. New customer additions are expected to boost revenue further. The team maintained operational efficiency to handle increased volume without significant cost increases, leading to margin growth.

Product Division revenue rose 16% to $0.72M in Q3-2025, driven by existing and new customer orders. Increased distributor activity is expected to bring new customers live in the next two quarters. Gross margins for both divisions improved, supporting revenue and margin growth.

Overall, the Company’s gross margin increased to 44% in Q3-2025, with a target of reaching 50%. Adjusted EBITDA, a non-GAAP measure, was $0.5M in Q3-2025, reflecting operational performance. The Company will host a shareholder call on November 17, 2025, to discuss quarterly performance and outlook.

Precipio focuses on cancer diagnostics with innovative solutions for accurate diagnoses. Their products and services aim to improve patient outcomes and reduce healthcare expenses. More information is available on their website and social media platforms. Forward-looking statements outline the Company’s growth targets and financial goals.

Read more at GlobeNewswire: Precipio Announces its Q3-2025 Financial Results